DB:MOL

Stock Analysis Report

Executive Summary

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Moleculin Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MOL has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.2%

MOL

5.1%

DE Biotechs

-0.4%

DE Market


1 Year Return

-19.5%

MOL

1.6%

DE Biotechs

10.4%

DE Market

Return vs Industry: MOL underperformed the German Biotechs industry which returned 1.6% over the past year.

Return vs Market: MOL underperformed the German Market which returned 10.4% over the past year.


Shareholder returns

MOLIndustryMarket
7 Day2.2%5.1%-0.4%
30 Day0.5%2.9%3.0%
90 Day-9.8%-5.3%11.1%
1 Year-19.5%-19.5%1.8%1.6%13.8%10.4%
3 Year-63.5%-63.5%66.3%64.2%24.8%13.8%
5 Yearn/a8.7%6.3%34.1%15.7%

Price Volatility Vs. Market

How volatile is Moleculin Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Moleculin Biotech undervalued compared to its fair value and its price relative to the market?

2.58x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MOL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MOL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MOL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MOL is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MOL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MOL is good value based on its PB Ratio (2.6x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Moleculin Biotech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

25.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MOL's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if MOL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MOL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Moleculin Biotech performed over the past 5 years?

-35.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MOL has a high level of non-cash earnings.

Growing Profit Margin: MOL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MOL is unprofitable, and losses have increased over the past 5 years at a rate of -35.4% per year.

Accelerating Growth: Unable to compare MOL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MOL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: MOL has a negative Return on Equity (-64.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Moleculin Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: MOL's short term assets ($18.6M) exceeds its short term liabilities ($11.1M)

Long Term Liabilities: MOL's short term assets ($18.6M) exceeds its long term liabilities (304.0K)


Debt to Equity History and Analysis

Debt Level: MOL is debt free.

Reducing Debt: MOL had no debt 5 years ago.


Balance Sheet

Inventory Level: MOL has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MOL's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MOL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MOL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -48.1% each year


Next Steps

Dividend

What is Moleculin Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MOL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MOL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MOL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MOL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MOL's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Moleculin Biotech's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Wally Klemp (59yo)

4.3yrs

Tenure

US$1,345,675

Compensation

Mr. Walter V. Klemp, also known as Wally, founded Moleculin Biotech, Inc. in July 2015 and has been its Chief Executive Officer since July 2015 and President since August 23, 2017. He is a Founder of Solit ...


CEO Compensation Analysis

Compensation vs Market: Wally's total compensation ($USD1.35M) is above average for companies of similar size in the German market ($USD215.15K).

Compensation vs Earnings: Wally's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.3yrs

Average Tenure

63yo

Average Age

Experienced Management: MOL's management team is considered experienced (3.3 years average tenure).


Board Age and Tenure

2.1yrs

Average Tenure

67yo

Average Age

Experienced Board: MOL's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.5%.


Management Team

  • Louis Ploth (65yo)

    Independent Advisor

    • Tenure: 3.3yrs
    • Compensation: US$118.49k
  • Wally Klemp (59yo)

    Founder

    • Tenure: 4.3yrs
    • Compensation: US$1.35m
  • Jon Foster (55yo)

    Executive VP & CFO

    • Tenure: 3.3yrs
    • Compensation: US$845.69k
  • Don Picker (73yo)

    Chief Scientific Officer

    • Tenure: 2.3yrs
    • Compensation: US$439.41k
  • Rob Shepard (67yo)

    Chief Medical Officer

    • Tenure: 3.4yrs
  • Waldemar Priebe

    Co-Founder and Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Sandra Silberman (63yo)

    Chief Medical Officer of New Products

    • Tenure: 2yrs
  • Jacqueline Northcut (57yo)

    Consultant

    • Tenure: 2.3yrs
    • Compensation: US$69.23k

Board Members

  • Wally Klemp (59yo)

    Founder

    • Tenure: 4.3yrs
    • Compensation: US$1.35m
  • Michael Cannon (74yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$100.70k
  • Jorge Cortes

    Member of Scientific Advisory Board

    • Tenure: 1.8yrs
  • John Waymack (67yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Waldemar Priebe

    Co-Founder and Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • John Climaco (50yo)

    Lead Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$110.70k
  • Elihu Estey

    Member of Scientific Advisory Board

    • Tenure: 1.8yrs
  • Martin Tallman

    Member of Scientific Advisory Board

    • Tenure: 0.7yrs
  • Robert George (69yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$106.95k
  • James Abbruzzese

    Member of Science Advisory Board

    • Tenure: 0.8yrs

Company Information

Moleculin Biotech, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moleculin Biotech, Inc.
  • Ticker: MOL
  • Exchange: DB
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$48.929m
  • Listing Market Cap: US$44.217m
  • Shares outstanding: 45.73m
  • Website: https://www.moleculin.com

Number of Employees


Location

  • Moleculin Biotech, Inc.
  • 5300 Memorial Drive
  • Suite 950
  • Houston
  • Texas
  • 77007
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MBRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2016
MOLDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2016
0K2HLSE (London Stock Exchange)YesCommon StockGBUSDJun 2016

Biography

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory ac ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/20 21:52
End of Day Share Price2019/11/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.